Combination HIV Treatment Awaits FDA Action


Gilead Sciences is seeking FDA approval for emtricitabine/tenofovir alafenamide.

Gilead Sciences is seeking FDA approval for its fixed-dose emtricitabine/tenofovir alafenamide (F/TAF) treatment for HIV-1 infection in adults and adolescents.

TAF is an investigational nucleotide reverse transcriptase inhibitor demonstrating high antiviral efficacy at a dose less than one-tenth of Gilead’s tenofovir disoproxil fumarate (Viread). It has also shown signs of improved renal and bone parameters compared with Viread in clinical trials.

The recommended dose of F/TAF is 200/25 mg, but if it is used in combination with a protease inhibitor administered with ritonavir or cobicistat, the recommended dose is 200/10 mg. The New Drug Application (NDA) for F/TAF seeks approval for both of these dosage strengths.

The FDA is expected to act on the NDA on November 5, 2015.

“Gilead has a long history of innovating HIV treatments, and with F/TAF, we have the potential to further optimize therapies for HIV patients who face a lifetime of antiretroviral treatment,” said Norbert Bischofberger, PhD, executive vice president of research and development and chief scientific officer for Gilead, in a press release. “With its high antiviral efficacy and favorable safety profile, F/TAF may offer an improved backbone for a new generation of HIV regimens.”

This filing marks Gilead's second F/TAF-based NDA, as it submitted one for a single-tablet HIV regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and TAF 10 mg (E/C/F/TAF) in November 2014.

Similar F/TAF-based HIV treatments are currently in development.

Related Videos
Image credit:  Gorodenkoff |
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin -
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny -
Various healthy foods -- Image credit: New Africa |
LGBTQIA+ pride -- Image credit: lazyllama |
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki |
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba |
© 2024 MJH Life Sciences

All rights reserved.